Treatment of osteoarthritis with continuous versus intermittent celecoxib

Journal of Rheumatology

Volumn 38, Issue 12, 2011, Pages 2625-2634

  Strand, Vibeke ^a   Simon, Lee S ^b   Dougados, Maxime ^c   Sands, George H ^d   Bhadra, Pritha ^d   Breazna, Aurora ^d   Immitt, Jeff ^e  

^a STANFORD UNIVERSITY   (United States)

^b SDG LLC   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PFIZER INC   (United States)

^e Execupharm Inc   (United States)

Author keywords

Continuous; COX 2 selective nonsteroidal antiinflammatory drugs; Flare; Intermittent; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; PARACETAMOL;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; WESTERN ONTARIO OSTEOARTHRITIS INDEX;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82755176059     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110636     Document Type: Article

References (31)

1. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD004257.
2. Managing osteoarthritis. NHS UK Website. [Internet. Accessed Aug 28, 2011.] Available from: http://www.nhs.uk/Conditions/Osteoarthritis/Pages/ Symptoms.aspx
3. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35.
4. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-41. (Pubitemid 19149397)
5. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006;20:3-25. (Pubitemid 43230460)
6. Dieppe P, Brandt KD. What is important in treating osteoarthritis? Whom should we treat and how should we treat them? Rheum Dis Clin North Am 2003;29:687-716. (Pubitemid 37296766)
7. Loeser RF, Shakoor N. Aging or osteoarthritis: which is the problem? Rheum Dis Clin North Am 2003;29:653-73. (Pubitemid 37296764)
8. Canadian Osteoarthritis Research Program (CORP). Study of arthritis in your community. Toronto: CORP Website; 2007. [Internet. Accessed Aug 28, 2011.] Available from: http://www.osteoarthritisresearch.ca/pdf/SAYC-2007winter.pdf
9. Majani G, Giardini A, Scotti A. Subjective impact of osteoarthritis flare-ups on patients' quality of life. Health Qual Life Outcomes 2005;3:14.
10. Brandt KD. The role of analgesics in the management of osteoarthritis pain. Am J Ther 2000;7:75-90.
11. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
12. Agency for Healthcare Research and Quality (AHRQ). Managing osteoarthritis: Helping the elderly maintain function and mobility. Rockville, MD: AHRQ Website. [Internet. Accessed Aug 28, 2011.] Available from: www.ahrq.gov/research/osteoria/osteoria.htm#self-manage
13. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6.
14. Pincus T, Fort JG, Mangal B, Koch G, Wolfe F, Moskowitz RW, et al. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib effectiveness study (PACES-1): a double-blind, randomized, cross-over clinical trial in patients with osteoarthritis of the hip or knee. Ann Rheum Dis 2003;62 Suppl 1:73.
15. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz RW, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9. (Pubitemid 38961917)
16. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
17. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619-26.
18. Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28.
19. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-R665.
20. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74. (Pubitemid 39140622)
21. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66. (Pubitemid 43255067)
22. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
23. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370:2138-51. (Pubitemid 350296305)
24. Luyten FP, Geusens P, Malaise M, De Clerck L, Westhovens R, Raeman F, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis 2007;66:99-106. (Pubitemid 46044867)
25. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
26. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105. (Pubitemid 30243242)
27. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.
28. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467-79. (Pubitemid 34036826)
29. Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23:213-27. (Pubitemid 32231112)
30. Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib. J Clin Rheumatol 2000;6:65-74. (Pubitemid 30226944)
31. Stengaard-Pedersen K, Ekesbo R, Karvonen AL, Lyster M. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology 2004;43:595.